Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP‐ribose) polymerases
Jun‐Xiang Zhang, Da‐Qiang Li, Aiwu Ruth He, Mona Motwani, Vasilis Vasiliou, Jeyanthy Eswaran, Lopa Mishra, Rakesh Kumar – 27 December 2011 – Hepatocellular carcinoma (HCC) is a particularly lethal form of cancer, yet effective therapeutic options for advanced HCC are limited. The poly(ADP‐ribose) polymerases (PARPs) and histone deacetylases (HDACs) are emerging to be among the most promising targets in cancer therapy, and sensitivity to PARP inhibition depends on homologous recombination (HR) deficiency and inhibition of HDAC activity blocks the HR pathway.